Floatz logo

ONATASERTIB

1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer

Qi ZhouSmall moleculePhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the 1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Qi Zhou
Phase 2CCC
Atg-010
Qi Zhou
Phase 2CC

Same molecule, other indications

ONATASERTIB is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
carcinoid tumorDormant
CC
Indicative ·
45 / 100
View asset →
hormone receptor-positive breast cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →